This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Journalology/ Peer Review/ Authorship  • Randomized Controlled Trial  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In his Commentary,¹ Dr Rennie asks, "Can manufacturers produce a worthwhile register?" As a pharmaceutical company that has created a register to communicate the results of clinical trials of our marketed products, GlaxoSmithKline (GSK) would like to bring to your attention the actions we have taken to make our register worthwhile to the medical profession and others with an interest in clinical research.

The GSK Clinical Trial Register is comprehensive: it will include the results from all GSK-sponsored clinical trials (phases 1-4) of marketed medicines conducted anywhere in the world. The results include primary and secondary efficacy end points defined in trial protocols and a summary of adverse events beyond what is traditionally reported in publications. The results are reported in the format of the International Conference on Harmonisation E3 guideline,² so that data can be compared across registers and, in time, possibly be brought together . . . [Full Text of this Article]

Ronald Krall, MD
Worldwide Development

Frank Rockhold, PhD
frank.w.rockhold@gsk.com
Biomedical Data Sciences
GlaxoSmithKline
Upper Merion, Pa

RELATED ARTICLES

Trial Registration: Ignored to Irresistible—Reply
Drummond Rennie
JAMA. 2005;293(2):158.
EXTRACT | FULL TEXT  

Trial Registration: A Great Idea Switches From Ignored to Irresistible
Drummond Rennie
JAMA. 2004;292(11):1359-1362.
EXTRACT | FULL TEXT